Fresenius SE Price to Book Ratio 2016-2025 | FSNUY
Historical price to book ratio values for Fresenius SE (FSNUY) over the last 10 years. The current price to book ratio for Fresenius SE as of June 25, 2025 is 1.25.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Fresenius SE Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2025-06-25 |
12.33 |
|
1.31 |
| 2025-03-31 |
10.39 |
$9.38 |
1.11 |
| 2024-12-31 |
8.49 |
$9.75 |
0.87 |
| 2024-09-30 |
9.34 |
$9.47 |
0.99 |
| 2024-06-30 |
7.30 |
$9.37 |
0.78 |
| 2024-03-31 |
6.60 |
$9.69 |
0.68 |
| 2023-12-31 |
7.58 |
$9.44 |
0.80 |
| 2023-09-30 |
7.62 |
$14.63 |
0.52 |
| 2023-06-30 |
6.76 |
$15.21 |
0.44 |
| 2023-03-31 |
6.38 |
$15.33 |
0.42 |
| 2022-12-31 |
6.62 |
$15.07 |
0.44 |
| 2022-09-30 |
5.08 |
$15.27 |
0.33 |
| 2022-06-30 |
7.14 |
$15.13 |
0.47 |
| 2022-03-31 |
8.53 |
$15.36 |
0.56 |
| 2021-12-31 |
9.25 |
$15.51 |
0.60 |
| 2021-09-30 |
11.06 |
$14.88 |
0.74 |
| 2021-06-30 |
11.99 |
$14.65 |
0.82 |
| 2021-03-31 |
10.07 |
$14.87 |
0.68 |
| 2020-12-31 |
10.44 |
$13.33 |
0.78 |
| 2020-09-30 |
10.27 |
$13.74 |
0.75 |
| 2020-06-30 |
10.95 |
$13.46 |
0.81 |
| 2020-03-31 |
8.23 |
$13.34 |
0.62 |
| 2019-12-31 |
12.45 |
$13.38 |
0.93 |
| 2019-09-30 |
10.33 |
$13.32 |
0.78 |
| 2019-06-30 |
12.00 |
$12.82 |
0.94 |
| 2019-03-31 |
12.14 |
$13.18 |
0.92 |
| 2018-12-31 |
10.53 |
$8.18 |
1.29 |
| 2018-09-30 |
15.96 |
$7.74 |
2.06 |
| 2018-06-30 |
17.45 |
$7.72 |
2.26 |
| 2018-03-31 |
16.40 |
$7.69 |
2.13 |
| 2017-12-31 |
16.79 |
$11.06 |
1.52 |
| 2017-09-30 |
17.33 |
$11.22 |
1.55 |
| 2017-06-30 |
18.39 |
$10.43 |
1.76 |
| 2017-03-31 |
17.18 |
$10.55 |
1.63 |
| 2016-12-31 |
16.70 |
$10.32 |
1.62 |
| 2016-09-30 |
17.01 |
$9.65 |
1.76 |
| 2016-06-30 |
15.59 |
$9.54 |
1.63 |
| 2016-03-31 |
15.47 |
$9.10 |
1.70 |
| 2015-12-31 |
15.15 |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$0.000B |
$23.628B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
